Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · LUPIN

LUPIN LTD.

HealthcarePharmaceuticals & Biotechnology₹90027 cr market cap
₹1998.80 ▲ +1.36% today As of 19 Nov 2026
52-week low ₹1922.0052-week high ₹2514.80

-21.6% from the 52-week high · +2.6% above the low

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 18,971 full-time employees. The firm is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The firm has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is engaged in the Anti-TB and Cephalosporins segments. The firm along with its subsidiaries has manufacturing locations spread across India, United States of America, Mexico and Brazil with trading and other incidental and related activities extending to the global markets. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept.

The short version. LUPIN LTD. reported revenue of ₹7,827 crore for Sep 2026, up 11.1% from a year earlier. Net profit was ₹1,155 crore (down 21.9% year on year). Return on equity was 23.8% in Mar 2026. Promoter holding was 46.84% in Sep 2026, down 0.11 points over 8 quarters.

1 · The price

How has the stock traded?

LUPIN LTD. trades 21.6% below its 52-week high and 2.6% above its 52-week low.

Change over period: —

1M+1.7%
3M-11.4%
6M-13.7%
1Y-3.7%

2 · The business

Is it growing?

Sales, year on year+11.1%

Sep 2026 revenue of ₹7,827 cr.

Profit, year on year-21.9%

Sep 2026 net profit of ₹1,155 cr.

Net margin14.8%

6.2 pts lower than a year earlier.

3-year growth131.5% profit

Revenue compounded at 19.3% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue78278277747571687048626856675768
Net profit115514151460117614781219773855
Net margin %14.817.119.516.421.019.413.614.8
EPS (₹)25.2630.9531.9425.7332.3626.6916.9218.74

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue2795822708200111664216405151631537516369
Net profit533332821914430-15281217-272607
Net margin %19.114.59.62.6-9.38.0-1.83.7
EPS (₹)116.6571.8842.019.45-33.6226.81-6.0213.4

3 · The quality

How well does it turn capital into profit?

Return on equity was 23.8% in Mar 2026; debt to equity is 0.26.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %23.819.113.43.5
Return on capital %28.421.317.67.2
EBITDA margin %30.623.919.511.2
Net margin %18.814.39.52.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR19.3%13.2%
Profit CAGR131.5%34.4%
Debt to equity0.26
Interest cover16.8x
Current ratio1.90
P/E ratio16.3

4 · The owners

Who holds it, and are they adding?

Promoter holding46.84%

Down 0.11 pts over 8 quarters.

Foreign institutions23.28%

Up 1.24 pts over 8 quarters.

Domestic institutions23.78%

Down 0.96 pts over 8 quarters.

Mutual fund schemes255

+55 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter46.9546.9246.946.946.8946.8546.8546.84-0.11
FII22.0421.4621.2520.4921.4921.7122.4223.28+1.24
DII24.7425.4125.5626.5525.5825.3224.6523.78-0.96
Public6.266.26.286.066.036.116.086.09-0.17

Mutual fund holdings · Oct 2026

255 schemes hold this stock

200 the month before.

  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND7.36% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund7.35% of NAV
  • NIPPON INDIA PHARMA FUND6.16% of NAV
  • Baroda BNP Paribas Health and Wellness Fund5.86% of NAV
  • Bandhan Healthcare Fund4.95% of NAV
  • Nippon India Nifty Pharma ETF4.83% of NAV
  • ICICI Prudential Nifty Pharma ETF4.83% of NAV
  • ICICI Prudential Nifty Pharma Index Fund4.83% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for LUPIN LTD. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about LUPIN LTD.

What is the LUPIN LTD. share price?

LUPIN LTD. (LUPIN) last closed at ₹1,998.80, up 1.36% on the day. Its 52-week range is ₹1,922.00 to ₹2,514.80.

What is the market cap of LUPIN LTD.?

LUPIN LTD. has a market capitalisation of about ₹90,027 crore. Its price-to-earnings ratio is 16.3.

How are LUPIN LTD.'s latest results?

LUPIN LTD. reported revenue of ₹7,827 crore for Sep 2026, up 11.1% from a year earlier. Net profit was ₹1,155 crore (down 21.9% year on year). Return on equity was 23.8% in Mar 2026. Promoter holding was 46.84% in Sep 2026, down 0.11 points over 8 quarters.

Who owns LUPIN LTD.?

As of Sep 2026, shareholding was: Promoter 46.84%, FII 23.28%, DII 23.78%, Public 6.09%.

How many mutual funds hold LUPIN LTD.?

255 mutual fund schemes held LUPIN LTD. in October 2026. That compares with 200 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 25 Jul 2025 · Final Dividend - Rs. 12
  • 16 Jul 2024 · Final Dividend - Rs. 8
  • 14 Jul 2023 · Final Dividend - Rs. 4
  • 14 Jul 2022 · Final Dividend - Rs. 4
  • 27 Jul 2021 · Final Dividend - Rs. 6.5
  • 03 Aug 2020 · Final Dividend - Rs. 6

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.